Company intelligence / Profile preview

IminoTech

Skokie, Illinois, USA

Ownership: Private
Employees: ~15
Development stage: Other

Overview

IminoTech specializes in the development and commercialization of iminosugars, a class of carbohydrate-based compounds that target alpha-glucosidase enzymes. Their lead product, Q-DNJ, is a concentrated iminosugar used for glycemic control and metabolic health.

Therapeutic areas: EndocrinologyInfectious DiseasesMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

ido-BR1

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

PhytoHealth Corporation

Beyond the preview

Go deeper on IminoTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IminoTech.

Explore the full profile